Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Synapse Awaits Humanitarian Approval For Diaphragm Pacing System To Treat ALS

This article was originally published in The Gray Sheet

Executive Summary

Synapse Biomedical expects FDA to issue a humanitarian device exemption within weeks allowing its NeuRX diaphragm pacing system to be marketed to treat patients with amytrophic lateral sclerosis.

You may also be interested in...



New Products In Brief

Synapse Biomedical’s NeuRx

New Products In Brief

Synapse Biomedical’s NeuRx

Synapse Biomedical Debuts Diaphragm Pacer, HDE-Cleared To Aid Breathing

Synapse Biomedical will pursue expanded approval of its diaphragm pacing system to facilitate breathing in patients with Lou Gehrig's disease after gaining a humanitarian device exemption June 17 for use by ventilator-dependent spinal cord injury patients, according to the company

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests

White House Takes Steps To Advance ‘Responsible’ AI That ‘Upholds Democratic Values’

UK MHRA Says Genetic Biobank Could Transform Drug Safety Monitoring Through Personalized Medicine

Wi-Fi Failures, Custom Tech And Other Challenges Of Bringing Specialty Care Into Patients’ Homes

See All
UsernamePublicRestriction

Register

MT030401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By